Compare Aehr Test Systems (AEHR) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Davita Inc — how do they compare? Aehr Test Systems trades at $117.8 (market cap $3.46B), while Davita Inc trades at $178.34 (market cap $11.72B). The key difference: Davita Inc is far larger — about 3.4× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| AEHR | DVA | |
|---|---|---|
Market Cap | $3.46B | $11.72B |
Sector | Technology | Health |
52-Week High | $117.18 | $240.96 |
52-Week Low | $17.38 | $103.87 |
Enterprise Value | $3.36B | $24.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.
Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
